Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia

Study Overview
=================
Brief Summary
-----------------
Glycogen storage disease type Ia (GSDIa) subjects retain a limited capacity for endogenous glucose production (EGP). To date, the origin of residual EGP in GSDIa patients is unknown. Either increased glycogen debranching or lysosomal glycogen breakdown can account for residual EGP in GSDIa. Innovative treatments for GSDIa (e.g. AAV8-mediated gene therapy and mRNA therapy) are being developed.Therefore, longitudinal minimally-invasive monitoring of outcomes after therapeutic interventions in GSD Ia subjects becomes warranted. The primary objective is to test the feasibility of EGP quantification in adult GSDIa subjects by stable isotopes after a single oral [6,6-2H2]glucose dose. Secondary objectives are to compare EGP assessed by a single oral [6,6-2H2]glucose dose (a) in GSDIa patients versus matched healthy participants, (b) among GSDIa patients, (c) in the pre-prandial state versus the fed state, (d) in the controlled hospital setting versus the home setting. Data collected from the continuous glucose monitoring data will also be compared

Detailed Description
-----------------
Study design: An investigator-initiated human pilot-study. Study population: Ten adult subjects with GSDIa and ten age and gender-matched healthy subjects. Interventions: Three experiments will be performed for each subject. During the first in hospital experiment, two oral D-[6,6-2H2]glucose loads will be performed 2 hours before breakfast and at lunchtime, respectively. The third oral D-[6,6-2H2]glucose load will be performed at home (random time). Capillary blood samples will be collected on filter paper at specific time points after each oral D-[6,6-2H2]glucose load. During the experiments, subjects will be monitored by subcutaneous continuous glucose monitoring (CGM).

Official Title
-----------------
Endogenous Glucose Production in Subjects With Glycogen Storage Disease Type Ia Estimated by a Single Oral Dose of Stable Isotopes: an Investigator-initiated Human Pilot Study

Conditions
-----------------
Glycogen Storage Disease Type IA

Intervention / Treatment
-----------------
* Biological: [6,6-2H2]glucose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The diagnosis should be confirmed by G6PC mutation analysis Age above 16 years Stable medical condition before the start of the test procedures Exclusion Criteria: Age < 16 years Intercurrent illness Recent history of hospitalization due to hypoglycemia Pregnancy History suggestive of diabetes or fasting intolerance First grade family member with a confirmed diagnosis associated with fasting intolerance

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients<br>GSDIa patients | Biological: [6,6-2H2]glucose<br>* Each subject will be administered two oral [6,6-2H2]glucose loads (pre-prandial, fed) in the hospital setting and one oral [6,6-2H2]glucose load at home setting (random time). Capillary blood samples will be collected on filter paper 10 times at specific time points after each oral [6,6-2H2]glucose load.<br>|
| Active Comparator: Controls<br>Healthy volunteers | Biological: [6,6-2H2]glucose<br>* Each subject will be administered two oral [6,6-2H2]glucose loads (pre-prandial, fed) in the hospital setting and one oral [6,6-2H2]glucose load at home setting (random time). Capillary blood samples will be collected on filter paper 10 times at specific time points after each oral [6,6-2H2]glucose load.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| [6,6-2H2]glucose concentration in GSDIa patients | Endogenous glucose production (EGP) in GSDIa will be assessed through minimal model calculation | every 10 minutes within the first hour as well as 75, 90 and 120 minutes after the oral load | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| [6,6-2H2]glucose concentration in GSDIa patients and matched healthy participants |  | every 10 minutes within the first hour as well as 75, 90 and 120 minutes after the oral load | 
| [6,6-2H2]glucose concentration in severe and attenuated GSDIa patients |  | every 10 minutes within the first hour as well as 75, 90 and 120 minutes after the oral load | 
| [6,6-2H2]glucose concentration in the pre-prandial state versus the fed state in GSDIa patients |  | every 10 minutes within the first hour as well as 75, 90 and 120 minutes after the oral load | 
| [6,6-2H2]glucose concentration in the pre-prandial state versus the fed state in healthy participants |  | every 10 minutes within the first hour as well as 75, 90 and 120 minutes after the oral load | 
| [6,6-2H2]glucose concentration in the controlled hospital setting versus the home setting in GSDIa patients |  | every 10 minutes within the first hour as well as 75, 90 and 120 minutes after the oral load | 
| [6,6-2H2]glucose concentration in the controlled hospital setting versus the home setting in healthy participants |  | every 10 minutes within the first hour as well as 75, 90 and 120 minutes after the oral load |